The FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population. The global market for GERD therapies is exp
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript
FLORHAM PARK, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint

Phathom Pharma Is A Buy Before July PDUFA

06:41am, Monday, 01'st Jan 2024
Phathom Pharmaceuticals' stock is down 35% from its August highs and is now trading at $9. The company has two approved indications for its drug vonoprazan and an upcoming PDUFA. Phathom has a cash ba
FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint

Following Up On Phathom Pharmaceuticals

12:43pm, Thursday, 05'th Oct 2023
Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug can
FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
One of the safest sectors on the market is biotech. After all, we can't stop people from aging — at least not yet.
Phathom Pharmaceuticals, Inc. is trading near 52-week highs. Despite its potential, there are reasons, like a competitive market, why we should take profits on Phathom Pharmaceuticals. If it falls bac
Phathom Pharmaceuticals (PHAT), Universal Stainless & Alloy Products (USAP) and Arlo Technologies (ARLO) are the breakout picks for today.
The mean of analysts' price targets for Phathom Pharmaceuticals, Inc. (PHAT) points to an 81.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong a
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong
Phathom Pharmaceuticals, Inc. (PHAT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PHAT's 50-day simple moving average broke out a
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE